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and meta-analysis
Deborah Bateson, Belinda E Butcher, Catherine Donovan, Louise Farrell, Gab Kovacs, Tonia Mezzini, Camille Raynes-Greenow, Gino Pecoraro, 
Christine Read, Rod Baber
ombined oral contraceptives (COCs) remain a widely used 
contraceptive method.1,2 General practitioners commonly 
see women for contraception-related consultations,1 and 
therefore must provide evidence-based information about the risks 
and benefits within the context of the full range of contraceptive 
options. The rise of social media as a source of medical information 
makes it important for healthcare professionals to counterbalance 
emotive misinformation and misperceptions about the risks of 
COCs, in particular the risk of venous thromboembolism (VTE), 
with balanced, easy-to-understand facts.
The earliest COCs contained relatively high doses of the 
synthetic oestrogen, ethinyl oestradiol (EE), in combination with 
the progestin levonorgestrel or norethisterone. Changes in COC 
formulations over the past 50 years have included a reduction 
in EE dose, substitution of EE with oestradiol and use of newer, 
receptor-selective progestins including desogestrel, gestodene, 
drospirenone and nomegestrol acetate. These changes have been 
aimed at reducing cardiovascular risks and troublesome side effects 
while potentially enhancing desirable ‘non-contraceptive’ effects.
In Australia, the annual incidence of VTE in the general 
community is approximately 0.6 cases per 1000 population.3 The 
incidence appears to be increasing in line with other high-income 
countries, which probably relates to an increase in diagnostic 
capability as well as increases in rates of modifiable risk factors 
such as obesity, smoking, long-distance travel and current COC 
use.4 Major non-modifiable VTE risk factors include increasing 
age and inherited coagulopathies, in particular factor V Leiden 
mutation.5 Current low-dose COC use (≤35 μg EE) is associated 
with an elevated VTE risk of twofold to threefold above baseline, 
which is highest in the first year of use. For most women of 
childbearing age, this translates into a very small absolute risk.2,6,7 
This absolute risk is also far less than that attributed to pregnancy 
Background
Much scientific, media and patient interest surrounds the risk 
of venous thromboembolism (VTE) in women taking combined 
oral contraceptives (COCs).
Objectives
We conducted a systematic review and meta-analysis to assess 
VTE risk in women taking COCs, focusing on drospirenone.
Methods
Literature searches of clinical studies on COCs in which VTE 
was reported were undertaken in May 2015. No overall estimate 
of VTE risk between drospirenone-containing COCs and other 
COCs was produced because of heterogeneity of the study 
designs.
Results
The final review and meta-analysis included 15 studies. 
No increased risk of VTE with drospirenone was seen in 
prospective or case control studies, but the risk of VTE was 
increased in retrospective cohort and nested case control 
studies.
Discussion
The difference in risk of VTE based on the choice of progestin 
in COCs is, at worst, very small in absolute terms and should 
not be the sole factor considered when choosing the ‘right’ 
COC for each woman.
C
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or the postpartum period (Table 1). An 
increasing body of international evidence 
points to the oestrogen component as 
the major contributor to VTE risk on the 
basis of the absence of an association 
for progestin-only contraceptives and an 
elevated risk for COCs containing more 
than 35 μg EE.8 However, international 
controversy remains regarding the 
influence of different progestins on VTE 
risk. Conflicting results from several 
European and US-based studies have led 
to confusion about whether certain COC 
formulations can safely be prescribed.9–13
In this paper, we present a systematic 
review and meta-analysis of all available 
evidence relating to the risk of VTE 
associated with drospirenone-containing 
COCs. We aim to support best-practice 
prescribing for medically eligible women 
choosing an oral method of contraception.
Methods
Study 
Methods of analysis and inclusion criteria 
were specified a priori and documented 
in a protocol. This systematic review was 
registered on PROSPERO (registration 
number CRD42014013589).
Data sources
We performed a systematic review 
of Medline, EMBASE, Derwent Drug 
File, Biosis, ISI – Current Contents, 
Chemical Abstracts and the International 
Pharmaceutical Abstracts, along with 
the Bayer internal company database. 
Searches were performed in August 2014 
and updated in May 2015. We searched 
for all clinical studies (prospective or 
retrospective observational studies 
or randomised controlled trials) in 
women taking the COC that compared 
drospirenone with other progestins, and 
included information on VTE incidence. 
We included studies in all languages, but 
excluded case studies and case series. 
Searches were independently conducted 
by two librarians.
Study selection
We identified 43 studies in our search, 
of which five were duplicates and were 
excluded. Of the remaining 38 studies, 
22 were excluded following abstract 
review (Figure 1). The included studies 
underwent quality appraisal using the 
MERGE criteria.14 One author completed 
the MERGE assessment, and a second 
author reviewed the assessment. A third 
author resolved disagreements between 
authors. Papers with a high risk of bias 
(MERGE category ‘C’) were excluded 
from the narrative review (one paper15 was 
excluded). The remaining 15 studies were 
included.9–13,16–25 Additional information 
for one study was obtained from a Food 
and Drugs Administration (FDA) briefing 
document.26 Characteristics of the included 
studies are reported in Table 2 (available 
online only).
Data extraction
Data extraction forms were piloted by two 
authors and modifications were made 
before sending to all authors for analysis. 
One author completed data extraction 
using the pre-defined data fields and a 
second author reviewed the extraction. 
A third author resolved disagreements 
between authors. We extracted 
information on participant demographics, 
study setting, comparators and relative 
risks of VTE. Given an anticipated high level 
of heterogeneity between the retrieved 
studies, we did not combine all studies 
meta-analytically to form one overall 
pooled risk estimate. We instead combined 
studies of similar type using Mantel-
Haenszel fixed effects meta-analysis to 
give a pooled estimate for each study type. 
As some studies reported odds ratios (OR) 
or relative risks (RR), while others reported 
hazard ratios (HR), methodological issues 
may arise with combining these different 
types of measures, leading to potential 
bias of the estimate by study group.27 
Therefore, a sensitivity analysis was 
conducted excluding the HR or the OR/
RR measure (depending on study type) to 
explore whether the study type estimates 
were stable. Heterogeneity was assessed 
using I2 measures.
Results (data synthesis)
Studies were grouped by type with a 
pooled estimate for each: prospective 
cohort (n = 4), retrospective cohort (n = 6), 
case-control (n = 2), nested case control 
(n = 3, including non-fatal idiopathic VTE 
(n = 2), and all VTE (n = 1)).
In the prospective cohort studies, 
there were no differences in VTE risk 
between those taking drospirenone-
containing COCs, compared with those 
taking levonorgestrel10,11,18 or other COCs21 
(combined RR = 0.94, 95% confidence 
interval [CI] = 0.75,1.18; Figure 2). This lack 
of difference remained when excluding the 
INGENIX study,21 which reported an RR 
(combined HR = 0.95, 95% CI = 0.74,1.21; 
Figure 3). No difference in risk was 
observed in the case control studies9,23 
either (combined RR = 1.21, 95%  
CI = 0.72, 2.02; Figure 2).
The retrospective cohort 
studies12,13,16,17,22,24 showed a significant 
increase in risk of VTE in women taking 
drospirenone-containing COC, compared 
with women taking levonorgestrel or 
other COCs (combined RR = 1.82, 95% 
CI = 1.60, 2.06; Figure 2). This increased 
Table 1. Risk of VTE in women at various life stages5,6
Population
Risk of VTE 
per 10,000 women per year
Women of childbearing age non-OC users 4
Women taking COC 7–10
Pregnant and postpartum women 20–30*
*Postpartum rates for the first 12 weeks postpartum have been quoted as 40–65 per 10,000 women per year,35 
and approximately 300–400 per 10,000 women per year during the two days before and the day after delivery36
COC, combined oral contraceptive; OC, oral contraceptive; VTE, venous thromboembolism
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risk was still observed when the Sidney 
study,22 which reported an HR, was 
excluded (combined RR = 1.83, 95% 
CI = 1.59, 2.10). An increased risk was 
also observed in the nested case control 
studies of idiopathic VTE19,20 (combined RR 
= 2.51, 95% CI = 1.82, 3.46; Figure 2) and 
all VTE25 (OR = 1.80, 95% CI = 1.49, 2.18; 
Figure 2).
Discussion
While current evidence supports a twofold 
to threefold increase in the risk of VTE for 
low-dose oestrogen-containing COCs (≤35 
μg EE)6 over non-use, the difference in risk 
between COC types on the basis of the 
progestin content remains controversial. 
Our systematic review of all available 
studies has found consistent differences 
in VTE outcomes for drospirenone-
containing COCs when compared with 
levonorgestrel and other COCs between 
studies with a retrospective or nested case 
control design, but not in case control and 
prospective cohort studies. 
Understanding the difference in VTE 
risk between COC preparations as well 
as between studies and study types is 
challenging for the clinician, and has been 
the subject of much debate. A randomised 
controlled trial might settle this issue, but 
given the rarity of VTE events, it is unlikely 
that one would ever be completed given 
the very large sample size that would 
be required. Restrictive inclusion criteria 
may also limit the generalisability of the 
data to everyday clinical practice. There 
are several known non-modifiable and 
modifiable VTE risk factors including older 
age, genetic predisposition, obesity and 
smoking,28 and it would be important to 
be able to adjust for these factors when 
making comparisons between progestins. 
In line with best-practice prescribing 
guidelines,2,29 COCs are contraindicated 
in women with known VTE risk factors, 
and non–oestrogen-containing alternative 
methods of contraception should be 
provided instead.28
Interpretation of the evidence has also 
been made more complex by phenomena 
such as an early user effect, reported 
in some studies, with increased risk of 
VTE events reported in new users of 
COCs.11,16,30 The mechanism for this 
increased risk in new users is poorly 
understood, but may be due to differential 
effects on sex hormone binding globulin 
or activated protein C resistance in early 
use, or by an unmasking of an underlying 
inherited coagulation disorder. The effects 
on coagulation parameters may explain the 
higher incidence of clotting after a COC 
break of four weeks or more.31 As user 
status may be more difficult to determine 
in retrospective database studies than 
in studies capturing this information 
prospectively from patients, it may result in 
unbalanced comparisons between groups. 
It should be noted that all of the included 
studies had limitations in design, including 
Figure 1. PRISMA flowchart
Records identified through  
database searching
n = 43
Records screened
n = 43
Records after duplicates removed
n = 38 
Full text articles assessed for eligibilty
n = 16
Duplicates excluded
n = 5
Excluded following abstract screening 
n = 22
A.  Not relevant to study question n = 8
B.  Review or editorial n = 3
C.  Papers on haemostatic variables n = 6
D.  Papers on arterial risk n = 1
E.  No comparison by progestin n=4
Excluded following full-text review
A.  Not of sufficient quality n = 1
Articles included in qualitative 
synthesis
n = 15
A.  Prospective cohort (n = 4)
B. Retrospective cohort (n = 6)
C.  Case-control (n = 2)
D.  Nested case control (n = 3), 
including non-fatal idiopathic VTE 
(n = 2) and all VTE (n = 1)
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differences in the inclusion criteria. The two 
large prospective observational studies 
(INAS-OC and EURAS)10,11 were sponsored 
by Bayer Healthcare as a requirement of 
the regulatory bodies. These studies had 
minimal inclusion/exclusion criteria and 
any woman who was seeking a new COC 
or switching COCs was eligible, which 
meant that some women with higher risk 
of thrombotic events were prescribed a 
COC despite not meeting current medical 
eligibility criteria. Many studies also had 
significant data limitations in relation to 
VTE-related risk factors. For example, many 
of the retrospective studies did not collect 
information about a current or previous 
history of VTE, or a family history of VTE.25,28 
Studies also did not report the presence 
of factor V Leiden mutation, which shows 
marked regional variation. It is estimated 
to affect 5% of the Australian population.32 
Despite the association with VTE, there is 
no indication for routinely screening women 
for factor V Leiden mutations prior to COC 
prescription. The COC is contraindicated 
in women with a known thrombogenic 
mutation,33 while caution is needed in those 
with a first-degree relative who experienced 
a VTE of any cause before the age of 45 
years, as the risks are thought to outweigh 
the benefits.28,33
The applicability of the study outcomes 
to the global population is difficult to 
ascertain. The women in the large 
prospective observational INAS-OC study 
were recruited from Europe and the 
US and, overall, were relatively young 
(mean age 26.3 years), had a mean body 
mass index (BMI) of 24.9 kg/m2 and 
were mainly non-smokers; only 16.9% 
of the cohort were obese (BMI ≥30 kg/
m2) and 22% were smokers. It is difficult 
to know whether these demographics 
can be generalised to other COC-taking 
populations such as Australian women. 
Unfortunately, information about BMI, 
obesity and smoking status was not 
routinely collected in many of the other 
included studies, particularly in the 
retrospective cohort studies, or was not 
captured in the database for all patients in 
nested case control studies.
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Figure 2. VTE risk in drospirenone users compared to other oral contraceptive users by study type  
ES, effect size (relative risk, odds ratio or hazard ratio)
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Figure 3. Sensitivity analysis of VTE risk in drospirenone users compared to other oral contraceptive users 
by study type. ES, effect size (relative risk, odds ratio or hazard ratio)
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Given the differences in results and 
study methods observed between the 
prospective and retrospective studies, 
it is difficult to determine the ‘truth’ in 
relation to VTE risk between different COC 
preparations. The retrospective studies had 
issues such as no validation of reported 
VTE events, insufficient risk factor data 
and possible provider bias due to selective 
prescribing of drospirenone-containing 
COC in higher risk women. The prospective 
cohort studies, especially those published 
more recently, may also suffer from 
prescriber bias in either direction, possibly 
due to the media influencing prescribing 
behaviour. Additionally, one might consider 
the lack of difference in studies funded by 
pharmaceutical companies as ‘evidence 
of influence’, although we note that on 
investigation these studies appear to be 
scientifically robust and independent. We 
cannot, therefore, exclude the possibility 
that the relative risk of VTE in women 
taking drospirenone-containing COC lies 
somewhere between the estimates of the 
prospective and retrospective analyses.
A strength of our study was the inclusion 
of the larger prospective studies and 
the use of adjusted risks where these 
were available. A recent network meta-
analysis by de Bastos and colleagues34 
examined VTE risk in women taking COCs. 
However, their analysis excluded the larger 
prospective studies (INAS, INGENIX, 
EURAS or LASS-OC; Table 2, available 
online only), as they restricted their 
focus to studies analysing the first VTE 
event, and the data entered into network 
meta-analysis was not adjusted for 
possible confounders. While excluding the 
prospective studies that included women 
who had experienced a previous VTE (in 
whom, therefore, COC use should have 
been contraindicated) may be seen as a 
strength of the meta-analysis by de Bastos 
and colleagues, it also potentially results 
in a loss of data from the vast majority of 
women who had not suffered a previous 
VTE event who were also included in these 
studies.
When making treatment decisions 
about prescribing COCs, consistent with 
evidence-based practice, individual risk 
factors for each woman must be carefully 
considered. Prescribers are encouraged to 
prescribe according to medical eligibility 
criteria and patient preferences. We believe 
those women who are eligible for COCs 
can use any COC with 35 μg of ethinyl 
oestradiol or less, or the newer oestradiol/
oestradiol valerate COCs (which are not 
included in this review because of lack 
of data). Those who are ineligible for an 
oestrogen-containing method due to VTE 
risk factors, including women with a high 
BMI and factor V Leiden mutation, should 
not be prescribed any COC.
Implications for general 
practice
The risk of VTE for any woman taking a 
low-dose COC (≤35 μg EE) is approximately 
two to three times higher than for non-
users. In absolute terms, risk of VTE is 
often quoted in the literature as 4/10,000 
women-years for non-pregnant non-users 
and 7–10/10,000 women years for COC 
users, which translates to a very low, 
acceptable absolute risk for any user when 
appropriate prescribing guidelines are 
applied. The question of whether or not the 
risk of VTE among users of drospirenone-
containing COCs is higher again cannot 
be definitively answered by the available 
scientific literature as the retrospective 
studies suggest an increased risk, whereas 
the prospective studies show no difference. 
However, this does, of itself, suggest that 
any change in absolute risk in drospirenone-
containing COCs must remain extremely 
small in absolute terms. The choice of 
contraceptive method should always be 
made together with the patient, on the 
basis of the evidence using appropriate 
medical eligibility criteria. We do not believe 
the available scientific evidence supports 
selective prescribing of COC based on 
‘differential’ VTE risk alone. COC choice 
should be based on other factors, including 
the side effect profile, potential additional 
benefits and cost. Ultimately, however, the 
choice of COC type is up to the woman 
herself with, ideally, expert, up-to-date 
evidence-based advice from her clinician.
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